Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution
| Autor: | Albert S. Klainer, Joseph E. Schwartz, Mark Palangio, Emil Bisaccia, Joselyn Gonzalez |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male medicine.medical_specialty Systemic disease Skin Neoplasms Time Factors medicine.medical_treatment Dermatology Gastroenterology Photopheresis Internal medicine Surveys and Questionnaires Antineoplastic Combined Chemotherapy Protocols medicine Adjuvant therapy Humans Stage (cooking) Aged Neoplasm Staging Retrospective Studies Response rate (survey) Aged 80 and over business.industry Cutaneous T-cell lymphoma Retrospective cohort study Middle Aged medicine.disease Lymphoma Surgery Lymphoma T-Cell Cutaneous Survival Rate Quality of Life Drug Therapy Combination Female business Follow-Up Studies |
| Zdroj: | Journal of the American Academy of Dermatology. 43(2 Pt 1) |
| ISSN: | 0190-9622 |
| Popis: | Background: Extracorporeal photochemotherapy (ECP; photopheresis) is a treatment option for cutaneous T-cell lymphoma (CTCL). Objective: This study describes the outcomes obtained with ECP alone or with adjuvant therapy in treating CTCL. Methods: A 9-year retrospective study was performed at a single institution. Results: Among 69 patients, 37 were treated with 6 months or more of ECP alone over an average of 36.9 months. Of these patients, 68% (25/37) had stage T2, 5% (2/37) had stage T3, and 27% (10/37) had stage T4 CTCL. Complete response (no skin or systemic disease for 1 month or more) and partial response (50%-99% skin improvement for 1 month or more) were achieved by 14% (5/37) and 41% (15/37) of patients, respectively, giving an overall response rate of 54% (20/37). In recalcitrant patients, adjuvant therapy significantly increased the response rate from 31% (4/13) to 69% (9/13) ( P = 0.004). ECP was well tolerated in the entire patient population. Conclusion: Response rates in this study compared favorably with those in previous studies, underscoring the potential value of ECP in treating CTCL. To our knowledge, this investigation included the largest group of CTCL patients ever treated with ECP at a single institution. (J Am Acad Dermatol 2000;43:263-71.) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect